Researchgene therapyophthalmologyocugenclinical trials
Ocugen Completes Enrollment For Phase 3 Trial
6.1
Ocugen Inc. (NASDAQ: OCGN) announced on March 2 that it completed enrollment of 140 patients in its Phase 3 liMeliGhT trial evaluating OCU400 for retinitis pigmentosa. The randomized 2:1 trial is gene-agnostic, uses a single injection per eye, and targets NR2E3 with a 12-month LDNA primary endpoint; topline data are expected in Q1 2027.
Key Points
- 1Completed enrollment of 140 patients randomized 2:1 in Phase 3 liMeliGhT trial.
- 2Highlights gene-agnostic OCU400 targeting NR2E3 to restore retinal gene networks across diverse RP mutations.
- 3Signals potential pathway-agnostic therapy; clinicians and researchers should monitor LDNA topline results in Q1 2027.
Scoring Rationale
Official Phase 3 enrollment news provides credible, timely update; limited novelty and narrow clinical scope reduce broader impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
